Pokaż uproszczony rekord

Eryptosis in polycythemia vera and essential thrombocythemia

dc.contributor.authorKopka, Paweł
dc.contributor.authorBliźniewska, Katarzyna
dc.contributor.authorTreliński, Jacek
dc.contributor.authorChojnowski, Krzysztof
dc.contributor.authorSicińska, Paulina
dc.contributor.authorDuchnowicz, Piotr
dc.contributor.authorBukowska, Bożena
dc.date.accessioned2021-10-15T08:08:44Z
dc.date.available2021-10-15T08:08:44Z
dc.date.issued2020
dc.identifier.issn0032-5449
dc.identifier.urihttp://hdl.handle.net/11089/39391
dc.description.abstractAim: Polycythemia vera (PV) and essential thrombocythemia (ET) are Philadelphia–negative myeloproliferative neoplasms with documented apoptosis impairment at the level of hematopoietic stem cell. However, so far no study has evaluated apoptosis of circulating blood neoplastic cells, including the suicidal death of erythrocytes – eryptosis. Material/Methods: Erythrocytes from 61 patients (24 PV and 37 ET) naïve to and treated with hydroxyurea (HU) and 13 healthy individuals were analysed using flow cytometry to quantify phosphatidylserine (PS) externalization from Annexin-V-binding, calpain activity from 7-amino-4-chloromethylcoumarin (CMAC)-fluorescence, cell volume from forward scattered light (FSC) and cell shape from side scattered light (SSC). Results: Significantly increased levels of calpain activity and PS exposure were observed in both ET and PV naïve patients, indicating enhanced eryptosis. Among HU-treated patients, a significant increase in calpain activity in the ET group and a decrease in the PV group were observed compared to patients without cytoreductive therapy. Among PV patients, FSC was substantially higher in the HU-treated group than in the naïve group, whereas no significant differences were found between HU-treated and HU-naïve groups of ET patients. Conclusions: The enhanced eryptosis in ET and PV patients may be a form of systemic compensation of the pathological bone marrow overproduction of erythrocytes. HU, the basic cytoreductive drug used in ET and PV, may affect eryptosis in PV and ET in different ways depending on disease. The JAK2V617F mutation was not observed to have any effect on eryptosis in ET.pl_PL
dc.description.sponsorshipThe study was supported by Medical University of Lodz grant number: 502-03/1-093-02/502-14-347.pl_PL
dc.language.isoenpl_PL
dc.publisherSciendo, De Gruyter Poland Sp. z o.o.; Instytut Immunologii i Terapii Doświadczalnej PANpl_PL
dc.relation.ispartofseriesPostępy Higieny i Medycyny Doświadczalnej / Advances in Hygiene and Experimental Medicine;74
dc.rightsUznanie autorstwa-Użycie niekomercyjne 4.0 Międzynarodowe*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectEssential thrombocythemiapl_PL
dc.subjectPolycythemia verapl_PL
dc.subjectEryptosispl_PL
dc.subjectHydroxyureapl_PL
dc.subjectJAK2V617F mutationpl_PL
dc.titleEryptosis in polycythemia vera and essential thrombocythemiapl_PL
dc.typeArticlepl_PL
dc.page.number69-76pl_PL
dc.contributor.authorAffiliationDepartment of Hemostasis Disorders, Medical University of Lodz, Department of Hematology, Copernicus Memorial Hospital, Lodz, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Hemostasis Disorders, Medical University of Lodz, Department of Hematology, Copernicus Memorial Hospital, Lodz, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Hemostasis Disorders, Medical University of Lodz, Department of Hematology, Copernicus Memorial Hospital, Lodz, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Hemostasis Disorders, Medical University of Lodz, Department of Hematology, Copernicus Memorial Hospital, Lodz, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Environmental Pollution Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Environmental Pollution Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Polandpl_PL
dc.contributor.authorAffiliationDepartment of Environmental Pollution Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Polandpl_PL
dc.identifier.eissn1732-2693
dc.referencesBerlin N.I., Lawrence J.H., Lee H.C.: The life span of the red bloodcell in chronic leukemia and polycythemia. Science, 1951; 114:385–387pl_PL
dc.referencesBerlin N.I., Reynafarcje C., Lawrence J.H.: Red cell life span inthe polycythemia of high altitude. J. Appl. Physiol., 1954; 7: 271–272pl_PL
dc.referencesBosman G.J., Willekens F.L., Werre J.M.: Erythrocyte aging: a morethan superficial resemblance to apoptosis? Cell Physiol. Biochem.,2005; 16: 1–8pl_PL
dc.referencesBratosin D., Estaquier J., Petit F., Arnoult D., Quatannens B., TissierJ.P., Slomianny C., Sartiaux C., Alonso C., Huart J.J., Montreuil J., AmeisenJ.C.: Programmed cell death in mature erythrocytes: a modelfor investigating death effector pathways operating in the absenceof mitochondria. Cell Death Differ., 2001; 8: 1143–1156pl_PL
dc.referencesCampbell P.J., Scott L.M., Buck G., Wheatley K., East C.L., MarsdenJ.T., Duffy A., Boyd E.M., Bench A.J., Scott M.A., Vassiliou G.S., MilliganD.W., Smith S.R., Erber W.N., Bareford D., Wilkins B.S., et al.:Definition of subtypes of essential thrombocythaemia and relationto polycythaemiavera based on JAK2 V617F mutation status: a prospectivestudy. Lancet, 2005; 366: 1945–1953pl_PL
dc.referencesDameshek W.: Some speculations on the myeloproliferative syndromes.Blood, 1951; 6: 372–375pl_PL
dc.referencesDaugas E., Cande C., Kroemer G.: Erythrocytes: death of a mummy.Cell Death Differ., 2001; 8: 1131–1133pl_PL
dc.referencesDeSesso J.M.: Cell death and free radicals: a mechanism for hydroxyureateratogenesis. Med. Hypotheses, 1979; 5: 937–951pl_PL
dc.referencesDogru G., Ay O.I., Erdal M.E., Ay M.E., Tombak A., Karakas U.: Therole of certain gene polymorphisms involved in the apoptotic pathwaysin polycythemia vera and essential thrombocytosis. Adv. Clin.Exp. Med., 2017; 26: 761–765pl_PL
dc.referencesFöller M., Huber S.M., Lang F.: Erythrocyte programmed celldeath. IUBMB Life, 2008; 60: 661–668pl_PL
dc.referencesFujita H., Sakuma R., Tomiyama J., Hamaki T., Ohwada A., KurosawaS., Nishimura S.: Increased phosphatidylserine exposure onthe erythrocyte membrane in patients with polycythaemiavera. Br.J. Haematol., 2011; 152: 238–240pl_PL
dc.referencesFujita H., Sakuma R., Tomiyama J., Hamaki T., Ohwada A., NishimuraS.: Relationship between clotting activity and phosphatidylserineexpression on erythrocyte membranes in polycythemia verapatients with the JAK2 V617F mutation. Arch. Physiol. Biochem.,2011; 117: 231–235pl_PL
dc.referencesGerotziafas G.T., Van Dreden P., Chaari M., Galea V., Khaterchi A.,Lionnet F., Stankovic-Stojanovic K., Blanc-Brude O., Woodhams B., Maier-Redelsperger M., Girot R., Hatmi M., Elalamy I.: The accelerationof the propagation phase of thrombin generation in patients withsteady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. Thromb. Haemost., 2012; 107: 1044–1052pl_PL
dc.referencesGiardina B., Messana I., Scatena R., Castagnola M.: The multiplefunctions of hemoglobin. Crit. Rev. Biochem. Mol. Biol., 1995; 30: 165–196pl_PL
dc.referencesHaynes J. Jr., Obiako B., Hester R.B., Baliga B.S., Stevens T.: Hydroxyureaattenuates activated neutrophil-mediated sickle erythrocytemembrane phosphatidylserine exposure and adhesion topulmonary vascular endothelium. Am. J. Physiol. Heart Circ. Physiol.,2008; 294: H379–H385pl_PL
dc.referencesJiang J., Jordan S.J., Barr D.P., Gunther M.R., Maeda H., MasonR.P.: In vivo production of nitric oxide in rats after administrationof hydroxyurea. Mol. Pharmacol., 1997; 52: 1081–1086pl_PL
dc.referencesKwaan H.C., Wang J.: Hyperviscosity in polycythemia vera andother red cell abnormalities. Semin. Thromb. Hemost., 2003; 29: 451–458pl_PL
dc.referencesLang K.S., Lang P.A., Bauer C., Duranton C., Wieder T., HuberS.M., Lang F.: Mechanisms of suicidal erythrocyte death. Cell Physiol.Biochem., 2005; 15: 195–202pl_PL
dc.referencesLaubach J.P., Fu P., Jiang X., Salter K.H., Potti A., Arcasoy M.O.:Polycythemia veraerythroid precursors exhibit increased proliferationand apoptosis resistance associated with abnormal RAS and PI3Kpathway activation. Exp. Hematol., 2009; 37: 1411–1422pl_PL
dc.referencesMalherbe J.A., Fuller K.A., Mirzai B., Kavanagh S., So C.C., Ip H.W.,Guo B.B., Forsyth C., Howman R., Erber W.N.: Dysregulation of theintrinsic apoptotic pathway mediates megakaryocytic hyperplasiain myeloproliferative neoplasms. J. Clin. Pathol., 2016; 69: 1017–1024pl_PL
dc.referencesNathan D.G., Berlin N.I.: Studies of the production and life spanof erythrocytes in myeloid metaplasia. Blood, 1959; 14: 668–682pl_PL
dc.referencesPhilips F.S., Sternberg S.S., Schwartz H.S., Cronin A.P., SodergrenJ.E., Vidal P.M.: Hydroxyurea. I. Acute cell death in proliferating tissuesin rats. Cancer Res., 1967; 27: 61–75pl_PL
dc.referencesRichter K., Bruschke G.: Erythrocyte life span in polycythemia vera;studies with radiochromium. Klin. Wochenschr., 1959; 37: 150–158pl_PL
dc.referencesRupon J.W., Domingo S.R., Smith S.V., Gummadi B.K., Shields H.,Ballas S.K., King S.B., Kim-Shapiro D.B.: The reactions of myoglobin,normal adult hemoglobin, sickle cell hemoglobin and hemin withhydroxyurea. Biophys. Chem., 2000; 84: 1–11pl_PL
dc.referencesSilva M., Richard C., Benito A., Sanz C., Olalla I., Fernández-LunaJ.L.: Expression of Bcl-x in erythroid precursors from patients withpolycythemia vera. N. Engl. J. Med., 1998; 338: 564–571pl_PL
dc.referencesTan X., Shi J., Fu Y., Gao C., Yang X., Li J., Wang W., Hou J., Li H.,Zhou J.: Role of erythrocytes and platelets in the hypercoagulablestatus in polycythemia vera through phosphatidylserine exposureand microparticle generation. Thromb. Haemost., 2013; 109:1025–1032pl_PL
dc.referencesTefferi A., Vannucchi A.M., Barbui T.: Essential thrombocythemiatreatment algorithm 2018. Blood Cancer J., 2018; 8: 2pl_PL
dc.referencesTefferi A., Vannucchi A.M., Barbui T.: Polycythemia vera treatmentalgorithm 2018. Blood Cancer J., 2018; 8: 3pl_PL
dc.referencesThiele J., Kvasnicka H.M.: A critical reappraisal of the WHO classificationof the chronic myeloproliferative disorders. Leuk Lymphoma,2006; 47: 381–396pl_PL
dc.referencesTong D., Yu M., Guo L., Li T., Li J., Novakovic V.A., Dong Z., TianY., Kou J., Bi Y., Wang J., Zhou J., Shi J.: Phosphatidylserine-exposingblood and endothelial cells contribute to the hypercoagulablestate in essential thrombocythemia patients. Ann. Hematol., 2018;97: 605–616pl_PL
dc.referencesTreliński J., Chojnowski K., Cebula-Obrzut B., Smolewski P.: Impairedapoptosis of megakaryocytes and bone marrow mononuclearcells in essential thrombocythemia: correlation with JAK2V617Fmutational status and cytoreductive therapy. Med. Oncol., 2012;29: 2388–2395pl_PL
dc.referencesVannucchi A.M., Guglielmelli P., Tefferi A.: Advances in understandingand management of myeloproliferative neoplasms. CACancer J. Clin., 2009; 59: 171–191pl_PL
dc.referencesVardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J.,Porwit A., Harris N.L., Le Beau M.M., Hellström-Lindberg E., TefferiA., Bloomfield C.D.: The 2008 revision of the World Health Organization(WHO) classification of myeloid neoplasms and acute leukemia:rationale and important changes. Blood, 2009; 114: 937–951pl_PL
dc.referencesYarbro J.W.: Mechanism of action of hydroxyurea. Semin. Oncol.,1992; 19 (3 Suppl. 9): 1–10pl_PL
dc.identifier.doi10.5604/01.3001.0014.0855
dc.disciplinenauki biologicznepl_PL


Pliki tej pozycji

Thumbnail
Nazwa:
license_rdf
Rozmiar:
914bajtów
Format:
application/rdf+xml
Oglądaj/Otwórz
Thumbnail
Nazwa:
1189943.pdf
Rozmiar:
284.8KB
Format:
PDF
Opis:
Article
Oglądaj/Otwórz

Pozycja umieszczona jest w następujących kolekcjach

Pokaż uproszczony rekord

Uznanie autorstwa-Użycie niekomercyjne 4.0 Międzynarodowe
Poza zaznaczonymi wyjątkami, licencja tej pozycji opisana jest jako Uznanie autorstwa-Użycie niekomercyjne 4.0 Międzynarodowe